Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT01564160

Assessment of PCSO-524 Relative to a Comparator Product

Assessment of the Acute and Chronic Bioavailability of Marine Lipid Fraction PCSO-524 Relative to a Comparator Product.

Sponsor: Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Conditions Healthy

Updated 7 times since 2017 Last updated: Nov 30, 2012 Started: Apr 30, 2012 Primary completion: Aug 31, 2012 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01564160, this EARLY_PHASE1 trial focuses on Healthy and remains completed. Sponsored by Nutrasource Pharmaceutical and Nutraceutical Services, Inc., it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2022 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jan 2022 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nutrasource Pharmaceutical and Nutraceutical Services, Inc.
Pharmalink International Ltd.

Data source: Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guelph, Canada